Kiniksa Pharmaceuticals International, plc (KNSA)
NASDAQ · Healthcare
Kiniksa Pharmaceuticals International, plc EBITDA 2021–2025
Kiniksa Pharmaceuticals International, plc annual/quarterly ebitda history and growth rate from 2021 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Kiniksa Pharmaceuticals International, plc ebitda for the quarter ending March 31, 2026 was 29.7 M, a 118.37% increase year-over-year.
- Kiniksa Pharmaceuticals International, plc ebitda for the twelve months ending March 31, 2026 was 16.7 M.
- Kiniksa Pharmaceuticals International, plc annual ebitda for 2025 was 78.8 M, a 279.36% decrease from 2024.
- Kiniksa Pharmaceuticals International, plc annual ebitda for 2024 was -43.9 M, a 92.17% increase from 2023.
- Kiniksa Pharmaceuticals International, plc annual ebitda for 2023 was -22.9 M, a 287.72% decrease from 2022.
- Kiniksa Pharmaceuticals International, plc annual ebitda for 2022 was 12.2 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Kiniksa Pharmaceuticals International, plc EBITDA — FAQ
Kiniksa Pharmaceuticals International, plc (KNSA) ebitda over the last 5 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see KNSA's ebitda history?
The chart and table above show Kiniksa Pharmaceuticals International, plc's ebitda by year and by quarter, including the growth rate.